Overexpression of Ubiquitin Specific Peptidase 14 Predicts Unfavorable Prognosis in Esophageal Squamous Cell Carcinoma

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2017 May 17

PMID 28509417

Citations 24

Authors

Baozhu Zhang

Mengqing Li

Pinzhu Huang

Xin-Yuan Guan

Ying-Hui Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Ubiquitin specific peptidase 14 (USP14), a deubiquitinating enzyme, has been documented as a key element to regulate the proteolysis function of proteasomes and an attractive therapeutic target for several cancers. Herein, we elucidate the role of USP14 in predicting the prognosis of patients with esophageal squamous cell carcinoma (ESCC).

Methods: USP14 expression was detected in ESCC tissues and matched adjacent non-tumorous tissues by quantitative real-time reverse transcription-PCR and immunohistochemistry. Kaplan-Meier survival analysis was used to assess the correlation between USP14 expression and prognosis in ESCC patients. Univariate and multivariate analysis was conducted with a Cox proportional hazards model to determine whether USP14 is an independent prognostic factor.

Result: Overexpression of USP14 was observed in approximately 60% of tested ESCC samples compared to their paired non-tumor esophageal tissues at both RNA and protein levels, and was significantly associated with distant metastasis (P = 0.001). Kaplan-Meier analysis showed that USP14 overexpression was related to poorer overall patient survival. Univariate and multivariate analyses demonstrated that USP14 was an independent risk factor for overall survival.

Conclusion: The findings in this study suggest that USP14 could be used as a potential prognostic marker for ESCC patients.

Citing Articles

Deubiquitinases as novel therapeutic targets for diseases.

Xian Y, Ye J, Tang Y, Zhang N, Peng C, Huang W MedComm (2020). 2024; 5(12):e70036.

PMID: 39678489 PMC: 11645450. DOI: 10.1002/mco2.70036.

USP14 inhibition by degrasyn induces YAP1 degradation and suppresses the progression of radioresistant esophageal cancer.

Yuan F, Xu J, Xuan L, Deng C, Wang W, Yang R Neoplasia. 2024; 60:101101.

PMID: 39675091 PMC: 11699344. DOI: 10.1016/j.neo.2024.101101.

Ubiquitination and deubiquitination in cancer: from mechanisms to novel therapeutic approaches.

Liu F, Chen J, Li K, Li H, Zhu Y, Zhai Y Mol Cancer. 2024; 23(1):148.

PMID: 39048965 PMC: 11270804. DOI: 10.1186/s12943-024-02046-3.

CircPDE5A-encoded novel regulator of the PI3K/AKT pathway inhibits esophageal squamous cell carcinoma progression by promoting USP14-mediated de-ubiquitination of PIK3IP1.

Lei K, Liang R, Liang J, Lu N, Huang J, Xu K J Exp Clin Cancer Res. 2024; 43(1):124.

PMID: 38658954 PMC: 11040784. DOI: 10.1186/s13046-024-03054-3.

PKCiota Inhibits the Ferroptosis of Esophageal Cancer Cells via Suppressing USP14-Mediated Autophagic Degradation of GPX4.

Tao H, Song S, Fan Z, Li W, Jin X, Jiang W Antioxidants (Basel). 2024; 13(1).

PMID: 38247539 PMC: 10812620. DOI: 10.3390/antiox13010114.

References

David D, Layfield R, Serpell L, Narain Y, Goedert M, Spillantini M . Proteasomal degradation of tau protein. J Neurochem. 2002; 83(1):176-85. DOI: 10.1046/j.1471-4159.2002.01137.x. View

Lee B, Lee M, Park S, Oh D, Elsasser S, Chen P . Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature. 2010; 467(7312):179-84. PMC: 2939003. DOI: 10.1038/nature09299. View

Wong M, Tao Q, Fu L, Wong K, Qiu G, Law F . Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma. Int J Oncol. 2006; 28(3):767-73. View

Zhu L, Yang S, He S, Qiang F, Cai J, Liu R . Downregulation of ubiquitin-specific protease 14 (USP14) inhibits breast cancer cell proliferation and metastasis, but promotes apoptosis. J Mol Histol. 2015; 47(1):69-80. DOI: 10.1007/s10735-015-9650-3. View

Tian Z, Darcy P, Wang X, Ray A, Tai Y, Hu Y . A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2013; 123(5):706-16. PMC: 3907756. DOI: 10.1182/blood-2013-05-500033. View

Chitta K, Paulus A, Akhtar S, Blake M, Caulfield T, Novak A . Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015; 169(3):377-90. PMC: 4846423. DOI: 10.1111/bjh.13304. View

Jarome T, Kwapis J, Hallengren J, Wilson S, Helmstetter F . The ubiquitin-specific protease 14 (USP14) is a critical regulator of long-term memory formation. Learn Mem. 2013; 21(1):9-13. PMC: 3867711. DOI: 10.1101/lm.032771.113. View

Brown R, Wahl R . Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993; 72(10):2979-85. DOI: 10.1002/1097-0142(19931115)72:10<2979::aid-cncr2820721020>3.0.co;2-x. View

Chuensumran U, Saelee P, Punyarit P, Wongkham S, Pairojkul C, Chauin S . Ubiquitin-specific protease 14 expression associated with intrahepatic cholangiocarcinoma cell differentiation. Asian Pac J Cancer Prev. 2011; 12(3):775-9. View

10.

Wing S . Deubiquitinases in skeletal muscle atrophy. Int J Biochem Cell Biol. 2013; 45(10):2130-5. PMC: 5734930. DOI: 10.1016/j.biocel.2013.05.002. View

11.

Li J, Zhang B, Qin Y, Bi J, Liu H, Li Y . CD68 and interleukin 13, prospective immune markers for esophageal squamous cell carcinoma prognosis prediction. Oncotarget. 2016; 7(13):15525-38. PMC: 4941258. DOI: 10.18632/oncotarget.6900. View

12.

Walters B, Campbell S, Chen P, Taylor A, Schroeder D, Dobrunz L . Differential effects of Usp14 and Uch-L1 on the ubiquitin proteasome system and synaptic activity. Mol Cell Neurosci. 2008; 39(4):539-48. PMC: 2734958. DOI: 10.1016/j.mcn.2008.07.028. View

13.

Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T . Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992; 69(2):277-84. DOI: 10.1002/1097-0142(19920115)69:2<277::aid-cncr2820690202>3.0.co;2-c. View

14.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

15.

Huang G, Li L, Zhou W . USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncol Rep. 2015; 34(6):2917-24. DOI: 10.3892/or.2015.4296. View

16.

Xu D, Shan B, Lee B, Zhu K, Zhang T, Sun H . Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. Elife. 2015; 4:e10510. PMC: 4733041. DOI: 10.7554/eLife.10510. View

17.

Yang C, Wang H, Wang Z, Du H, Tao D, Mu X . Risk factors for esophageal cancer: a case-control study in South-western China. Asian Pac J Cancer Prev. 2005; 6(1):48-53. View

18.

Wu N, Liu C, Bai C, Han Y, Cho W, Li Q . Over-expression of deubiquitinating enzyme USP14 in lung adenocarcinoma promotes proliferation through the accumulation of β-catenin. Int J Mol Sci. 2013; 14(6):10749-60. PMC: 3709700. DOI: 10.3390/ijms140610749. View

19.

Burcoglu J, Zhao L, Enenkel C . Nuclear Import of Yeast Proteasomes. Cells. 2015; 4(3):387-405. PMC: 4588042. DOI: 10.3390/cells4030387. View

20.

Darcy P, Brnjic S, Olofsson M, Fryknas M, Lindsten K, De Cesare M . Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med. 2011; 17(12):1636-40. DOI: 10.1038/nm.2536. View